Pomerantz Law Firm Probes Potential Investor Claims Against ACADIA Pharmaceuticals
Investigation into ACADIA Pharmaceuticals by Pomerantz LLP
On October 8, 2026, Pomerantz LLP announced that they are delving into claims regarding potential legal violations by ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and certain personnel within the company. The firm is seeking to determine whether any instances of securities fraud or unlawful business practices have occurred, which might have negatively impacted investors in ACADIA. Investors who may be involved are encouraged to contact Danielle Peyton at Pomerantz for further assistance.
This investigation gains context from a press release issued by ACADIA on September 24, 2026, where the company revealed topline results from the second phase of its RADIANT clinical trial evaluating the drug remlifanserin. This trial was designed to assess its effectiveness in treating hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). However, the data indicated that the trial's primary endpoint was
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.